MedDataX Logo

Biomarker and DNA Collection in Subjects Participating in Protocol 22003

NCT ID: NCT00892580

Last Updated: 2013-07-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

32 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22003 will be offered participation in 22003A which will evaluate secreted protein before and after treatment with STX209 and placebo to determine if they correlate with effectiveness of treatment or susceptibility to treatment with STX209. These same subjects will also be asked to contribute a blood sample for DNA (deoxyribonucleic acid) collection. The investigators will study the DNA to determine if STX209 works better in people with specific gene variations, or to find new gene variations that predict how well STX209 works.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fragile X Syndrome

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

fragile X syndrome biomarkers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

STX209

collection of serum for DNA to elucidate a potential biomarker for patients with ASD

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Inclusion Criteria:

* The Autism Spectrum Disorder subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22003

Exclusion Criteria:

* The Autism Spectrum Disorder subjects that meet the inclusion and exclusion criteria and consent to participate in protocol 22003
Minimum Eligible Age

6 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Seaside Therapeutics, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Craig Erikson, MD

Role: PRINCIPAL_INVESTIGATOR

Riley Hospital for Children

Bryan King, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Seattle Children's Hospital

James McCracken, MD

Role: PRINCIPAL_INVESTIGATOR

University of California, Los Angeles

Lawrence Scahill, PhD

Role: PRINCIPAL_INVESTIGATOR

Yale University

Linmarie Sikich, MD

Role: PRINCIPAL_INVESTIGATOR

University of North Carolina Neurosciences Hospital

Jeremy Veenstra-VanderWeele, MD

Role: PRINCIPAL_INVESTIGATOR

Vanderbilt Kennedy Center

Lawrence Ginsberg, MD

Role: PRINCIPAL_INVESTIGATOR

Red Oaks Psychiatry Associates, PA

Raun Melmed, MD

Role: PRINCIPAL_INVESTIGATOR

Southwest Autism Research & Resource Center

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Southwest Autism Research & Resource Center

Phoenix, Arizona, United States

Site Status

University of California-Los Angeles Neuropsychiatric Institute

Los Angeles, California, United States

Site Status

Yale Child Study Center

New Haven, Connecticut, United States

Site Status

Riley Hospital for Children

Indianapolis, Indiana, United States

Site Status

University of North Carolina Neurosciences Hospital

Chapel Hill, North Carolina, United States

Site Status

Vanderbilt Kennedy Center

Nashville, Tennessee, United States

Site Status

Red Oaks Psychiatry Associates, PA

Houston, Texas, United States

Site Status

Seattle Children's Hospital

Seattle, Washington, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

22003A

Identifier Type: -

Identifier Source: org_study_id